Search Type: drug or dietary supplement name
Search Term: galantamine (RAZADYNE, RAZADYNE ER)


Worst Pills, Best Pills Newsletter Articles

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a primary subject of discussion

Disease and Drug Family Information

Search results below include Disease and Drug Family Information where your selected drug is a primary subject of discussion
  • Alzheimer's Disease [hide all summaries]
    The strategy to sell Alzheimer’s disease drugs is based on hope, fear, and guilt: hope that one of these drugs might work, fear that if one of these drugs is not started quickly, all will be lost; and guilt if family members have not made the decision to fight the disease with expensive, sometimes dangerous, drugs. Recent reviews by the U.S. Preventive Services Task Force and the American Academy of Neurology are appropriately skeptical of the use of these drugs.

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion
  • False-Hope Alzheimer’s Disease Drugs [hide all summaries]
    (October 2018)
    The FDA has approved four drugs for treating Alzheimer’s disease, a devastating brain disorder that affects nearly 6 million Americans, most of whom are elderly. Learn why we have designated each of these drugs as Do Not Use.
  • Drugs That Cause Loss of Bladder Control [hide all summaries]
    (February 2016)
    Urinary incontinence, or loss of bladder control, is a common and often embarrassing problem that can have a huge impact on quality of life. Find out which drugs can cause this problem.
  • Canada Issues Warnings on Alzheimer’s Disease Drugs [hide all summaries]
    (June 2015)
    Health Canada, the Canadian equivalent of the U.S. Food and Drug Administration, recently warned physicians and patients about safety concerns regarding two drugs commonly used to treat Alzheimer’s disease. Find out the names of these drugs and the newly identified serious adverse events linked to them.
  • Revisiting Memantine (NAMENDA) and Other Alzheimer’s Disease Drugs [hide all summaries]
    (July 2011)
    Find out what outside experts, in published medical journal articles, think about the usefulness of the currently available drugs for treating Alzheimer's disease.
  • New Study Further Links Alzheimer's Drugs to Side Effects [hide all summaries]
    (August 2009)
    We review evidence from a recently-published medical journal article that syncope (fainting), often leading to falls, can be a serious side effect of the Alzheimer’s disease drugs donepezil (ARICEPT), rivastigmine (EXELON) and galantamine (REMINYL). In addition, hospitalizations for slow heart rhythms, pacemaker insertions and hip fractures — all of which can be related to syncope — increased in patients using these Alzheimer’s drugs. This, along with their questionable effectiveness, further increases the evidence underlying our recommendation not to use these drugs.
  • A Review of Alzheimer’s Drugs: Donepezil (ARICEPT), Rivastigmine (EXELON), and Galantamine (REMINYL) [hide all summaries]
    (October 2005)
    This article outlines a recent systematic review of all published, gold standard clinical trials of the Alzheimers disease drugs donepezil (ARICEPT), rivastigmine (EXELON), and galantamine (REMINYL).
  • Deaths Attributed To The Alzheimer’s Disease Drug Galantamine (REMINYL) [hide all summaries]
    (March 2005)
    There is no evidence that this drug leads to substantial functional improvement or prevents the progression of the disease, and new evidence indicates that it may increase the risk of death.
  • Drugs for Alzheimer's Disease [hide all summaries]
    (July 2004)
    Although, according to the New York Times, “a million Americans take them, at an overall cost of $1.2 billion a year.”, a professor at Johns Hopkins University School of Medicine who is an expert in Alzheimer’s disease was quoted in the article and placed the value of the current crop of Alzheimer’s drugs in perspective when he said, “You can name 11 fruits in a minute instead of 10. Is that worth 120 bucks a month?”

SHOW secondary search results for galantamine (RAZADYNE, RAZADYNE ER)

Copyright © 2018 Public Citizen's Health Research Group. All rights reserved. https://www.worstpills.org/